Capula Management LTD Gilead Sciences, Inc. Call Options Transaction History

Capula Management LTD

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $4.14 Million - $4.73 Million	-54,500 Reduced 93.0%	4,100 $315,000
Q1 2023 May 10, 2023	SELL	$77.31 - $88.08 $139,158 - $158,544	-1,800 Reduced 2.98%	58,600 $4.86 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $22.4 Million - $32.2 Million	-360,100 Reduced 85.64%	60,400 $5.19 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $20.7 Million - $23.7 Million	348,500 Added 484.03%	420,500 $25.9 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $4.16 Million - $4.68 Million	72,000 New	72,000 $4.45 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $3.29 Million - $3.6 Million	-51,900 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $3.11 Million - $3.55 Million	51,900 New	51,900 $3.35 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.